🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the UK / NCT01357668
Active, not recruiting Observational

An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis

NCT01357668 · tracked via the Priya Life Science UK tracker
Sponsor
Bristol-Myers Squibb
Phase
Observational
Started
2013-01-30
Last updated
2025-09-25

Condition(s) studied

Juvenile Idiopathic Arthritis

Study summary

The purpose of this study is to examine the long-term safety of Abatacept for the treatment of juvenile idiopathic arthritis (JIA) with particular in interest in the occurrence of serious infections, autoimmune disorders, and malignancies.

Eligibility

Sex
ALL
Min age
Max age
17 Years
Healthy volunteers
No
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria * Diagnosis of JIA (any subtype) * Age \< 18 years at the time of enrollment unless currently or previously enrolled in an abatacept clinical trial and received abatacept * Receiving Abatacept at the time of enrollment as per treating physician's decision or received abatacept in a clinical trial * Parent or legally acceptable representative willing to participate in the study and sign the informed consent Exclusion Criteria * Pregnant or nursing female at the time of enrollment * Prior malignancies if the patient has not been malignancy free for at least 5 years. * Any serious acute or chronic medical condition other than JIA, including chronic infection, which would compromise the patient's ability to participate in the study * Known poor compliance with clinic visits (based on physician judgment).

Primary outcome measure(s)

Trial sites (59)

FacilityCityRegionStatus
Local Institution - 0060 Little Rock Arkansas
Local Institution - 0001 Princeton New Jersey
Local Institution - 0059 Cincinnati Ohio
Local Institution - 0025 Bregenz Austria
Local Institution - 0002 Innsbruck Austria
Local Institution - 0032 Vienna Austria
Local Institution - 0010 Botucatu São Paulo
Local Institution - 0026 Campinas São Paulo
Local Institution - 0028 São Paulo São Paulo
Local Institution - 0027 Rio de Janeiro Brazil
Local Institution - 0029 Calgary Alberta
Local Institution - 0011 Montreal Quebec
Local Institution - 0035 Aarhus Central Jutland
Local Institution - 0012 Copenhagen Denmark
Local Institution - 0040 Clermont-Ferrand Puy-de-Dôme
Local Institution - 0005 Paris France
Local Institution - 0041 Toulouse France
Local Institution - 0003 Bad Bramstedt Germany
Local Institution - 0030 Berlin Germany
Local Institution - 0034 Freiburg im Breisgau Germany
Local Institution - 0031 Hamburg Germany
Local Institution - 0033 Heidelberg Germany
Local Institution - 0016 Thessaloniki Greece
Local Institution - 0017 Budapest Hungary
Local Institution - 0014 Jerusalem Israel
Local Institution - 0042 Florence Italy
Local Institution - 0015 Genova Italy
Local Institution - 0043 Naples Italy
Local Institution - 0045 Naples Italy
Local Institution - 0044 Padova Italy
Local Institution - 0046 Trento Italy
Local Institution - 0018 Riga Latvia
Local Institution - 0006 Guadalajara Jalisco
Local Institution - 0047 Rotterdam Netherlands
Local Institution - 0019 Utrecht Netherlands
Local Institution - 0048 Tromsø Norway
Local Institution - 0049 Trondheim Norway
Local Institution - 0007 Lima Peru
Local Institution - 0050 Lima Peru
Local Institution - 0020 Lisbon Portugal

+ 19 more sites — see the full list on the official registry below.

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT01357668 on ClinicalTrials.gov ↗ ← All trials in the UK